Compare ON & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ON | NTRA |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1B | 45.3B |
| IPO Year | 2000 | 2015 |
| Metric | ON | NTRA |
|---|---|---|
| Price | $72.11 | $328.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 15 |
| Target Price | $65.29 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 9.3M | 1.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $5,878,300,000.00 | $210,939,000.00 |
| Revenue This Year | $7.93 | $18.08 |
| Revenue Next Year | $8.90 | $19.65 |
| P/E Ratio | $147.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.56 | $157.43 |
| 52 Week High | $134.92 | $333.56 |
| Indicator | ON | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 33.35 | 68.06 |
| Support Level | $54.93 | $187.64 |
| Resistance Level | $73.76 | N/A |
| Average True Range (ATR) | 2.95 | 10.93 |
| MACD | -0.15 | 1.95 |
| Stochastic Oscillator | 9.09 | 90.53 |
Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and one of the largest suppliers of image sensors to the automotive market. Its chips sell into vehicle drivetrains, automotive safety systems, energy infrastructure, industrial automation, and data centers. Onsemi manufactures most of its products in-house, vertically integrated from design to production. Its sales are split between direct and distribution, and it holds a global manufacturing and customer footprint.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.